Boehringer Ingelheim Registers Phase III Trial Investigating Verducatib in COPD
October 31, 2026
October 31, 2026
INGELHEIM AM RHEIN, Germany, Oct. 31 -- Boehringer Ingelheim, a pharmaceutical company, issued the following news release:
* * *
Boehringer Ingelheim registers Phase III trial investigating verducatib in COPD
Ingelheim, Germany and Ridgefield, Conn., U.S, Fri, 30/10/2026
* The Phase III AIRWARD(TM) trial was published today on ClinicalTrials.gov (NCT07907991)./1
* AIRWARD will evaluate the efficacy and safety of verducatib, an inve . . .
* * *
Boehringer Ingelheim registers Phase III trial investigating verducatib in COPD
Ingelheim, Germany and Ridgefield, Conn., U.S, Fri, 30/10/2026
* The Phase III AIRWARD(TM) trial was published today on ClinicalTrials.gov (NCT07907991)./1
* AIRWARD will evaluate the efficacy and safety of verducatib, an inve . . .